Gainers
Bon Natural Life Limited (NASDAQ: BON) climbed 24.2% to $4.11 following FY21 results. Bon Natural Life reported FY21 earnings of $0.68 per share on sales of $25.5 million.
Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company, based on Sorbonne University campus and focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today announces that it has received approval from